Research & Development
Research and Development: Medical & Scientific Affairs
Teva Neuroscience’s medical and scientific functions include medical affairs and clinical research.
The medical affairs function primarily provides support to health care providers and patients through medical information, scientific communications and educational activities. The group is also responsible for phase IV studies, supporting the other functional areas within Teva Neuroscience to further advance the understanding of neurological disorders and evaluate new product opportunities.
Product pipeline
The clinical research unit, formally established in 2003, focuses on phase II/III clinical studies. Most of the research projects are focused on neurological and auto-immune diseases. The group continues to investigate product improvements and new indications for our currently marketed products:
- COPAXONE® (glatiramer acetate) for Multiple Sclerosis (MS)
- AZILECT® (rasagiline mesylate) for Parkinson's disease (PD)
- Other new products for MS and other neurological and auto-immune diseases
The group is involved in the conduct of global studies but can also design and implement new innovative projects in collaboration with Canadian scientists. Through all those efforts, the associates working in the various scientific functions improve the delivery of services to patients affected by those diseases and develop new products that will improve their health outcomes.
We invite you to visit the links below, where you will find detailed information on the status of our various clinical research initiatives: